The Circulating Tumor Biomarkers team is seeking a highly motivated scientist for a funded project aiming at detecting microsatellite instability (MSI) from liquid biopsies.
We are a collaborative group of scientists and clinicians, part of the Translational Research Department of the Institut Curie. The institute is located in the heart of Paris and offers a highly stimulating and dynamic multidisciplinary research environment.
Circulating tumor biomarkers are revolutionizing cancer care. They represent an alternative to tissue biopsies for cancer prognosis and genetic profiling, and a promising tool for real-time monitoring of treatment efficacy. Our group has initiated and coordinated numerous studies that have helped to establish the clinical validity of circulating tumor cells (CTCs) in metastatic and early breast cancer (1, 2). Our work has also demonstrated that circulating tumor DNA (ctDNA) can be used as a surrogate to tumor biopsies (3), as a prognostic factor (4) and as a marker of tumor response to treatment (5). More recently, we have also demonstrated the use of ctDNA to evaluate minimal residual disease, detect early relapse, as well as the acquisition of resistant mutation during therapy (6). Our group is also actively involved in the development of innovative approaches for improved detection and better characterization of CTCs and ctDNA (7, 8).
MSI has recently emerged as a predictive pan-tumor biomarker of immunotherapy efficacy, and its detection from blood represents a promising tool for therapeutic decisions and post-treatment monitoring of the disease (9). The candidate will work on the improvement of a recently developed method capable of detecting MSI on ctDNA (Silveira et al, in preparation; patent pending) and on the development of a diagnostic test capable of detecting MSI from multiple cancer types.
The ideal candidate should hold a PhD in Biology with a background in molecular biology and/or cancer genetics. This project will require hands-on experience with molecular biology tools and a strong knowledge in next generation sequencing technologies. Experience in computational genomics will be an asset. A good level of English is also required.
Applicants should send their CV, a cover letter and the contact of two references to Charlotte.Proudhon@curie.fr
1. Bidard et al., Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. The Lancet Oncology. 15, 406 (2014).
2. Bidard et al., Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. JNCI: Journal of the National Cancer Institute. 12, 335–8 (2018).
3. Lebofsky et al., Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Molecular Oncology. 9, 783–790 (2015).
4. Bidard et al., Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. International Journal of Cancer. 134, 1207–1213 (2014).
5. Riva et al., Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Clin. Chem., clinchem.2016.262337–9 (2017).
6. Jeannot et al., A single droplet digital PCR for ESR1 activating mutations detection in plasma. bioRxiv, 507608 (2019).
7. Decraene et al., Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR. Clin. Chem. 64, 317–328 (2018).
8. Decraene et al., Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions. JoVE, 1–10 (2018).
9. Cabel et al., Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nature Reviews Clinical Oncology. 112, E5503 (2018).